News

Nabi initiated this clinical trial in March 2010 and expects to have final data in early 2012. The first clinical trial was initiated in November 2009 and completed

The Emblem study was designed to evaluate the efficacy and safety of Epratuzumab (in combination with immunosuppressants) in SLE, identify an optimal dose and regimen for further studies,

WuXi PharmaTech has posted a net income of $44.26m for the third quarter 2010, or $0.59 per diluted share, compared to net income of $14.33m, or $0.19 per

Vyteris is the maker of the first active, ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US Food and Drug Administration. Vyteris said that the

Immunologix holds the exclusive worldwide license rights to a proprietary technique used to produce fully human antibodies. GenScript claimed that it offers antibody drug services that include antigen

Phytomedics is a healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources. PMI-001 is a novel, oral, disease-modifying, botanical drug for

Scynexis, a drug discovery and development company, directs medicinal chemistry, advanced biological screening, bioanalytical and ADMET activities towards Merial’s animal health discovery efforts. Scynexis president and CEO Yves

As per the terms of the agreement, Biovista will collaborate with Pfizer’s Indications Discovery Unit to identify up to three novel indications for each of the Pfizer candidates.

The collaboration is designed to create new opportunities to further improve the efficacy of several of Merial’s new vaccine development targets. In Cell Art claims that the ICA614